Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03RXS
|
|||
| Drug Name |
TAK-831
|
|||
| Indication | Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Phase 2 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Phase 1 | [2] | ||
| Company |
Takeda Deerfield, IL
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | D-amino acid oxidase (DAO) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| D-Arginine and D-ornithine metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Peroxisome | ||||
| Pathwhiz Pathway | Arginine and Proline Metabolism | |||
| D-Arginine and D-Ornithine Metabolism | ||||
| WikiPathways | Metabolism of amino acids and derivatives | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.